Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug shows promise for rare gut and lung tumors

NCT ID NCT07272512

Disease control Sponsor: Shanghai Zhongshan Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study is testing an oral drug called surufatinib in 350 adults with advanced neuroendocrine tumors (NETs). The drug works by cutting off blood supply to tumors and boosting the immune system. Researchers want to see if it helps control the disease and improves survival in real-world settings, not just in strict clinical trials.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Surufatinib (an oral drug that targets blood vessel growth and immune signals)
What this could lead to
If successful, this study could confirm surufatinib as a standard treatment option to slow tumor growth and extend survival for people with advanced neuroendocrine tumors.
What could go wrong
This is a single-arm, real-world study without a comparison group, so results may be less definitive. Side effects like high blood pressure, fatigue, or liver issues are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 350 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2025

Expected to finish

Nov 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adequately understand the study and voluntarily sign the Informed Consent Form. * Have a confirmed histological or cytological diagnosis of neuroendocrine neoplasm. * Have measurable disease based on RECIST 1.1. * Have adequate organ and bone marrow function. * Life expectancy \> 12 weeks. * Women of childbearing age must be willing to use adequate contraceptives during the study period of drug treatment. Exclusion Criteria: * Other malignant tumors diagnosed within 5 years (excluding effectively treated basal cell carcinoma, cutaneous squamous cell carcinoma, or completely resected in situ cervical/breast cancer). * Concurrent use of other investigational drugs or approved/investigational anti-tumor therapies. * Contraindications to surufatinib: active bleeding, ulcers, intestinal perforation/obstruction, uncontrolled hypertension, grade III-IV cardiac insufficiency, \<30 days post-major surgery, or severe hepatic/renal impairment. * Pregnant (positive pre-treatment pregnancy test) or lactating females. * Massive pleural effusion/ascites requiring drainage. * Other diseases/abnormalities (metabolic, physical, or laboratory) deemed by the investigator to preclude study drug use.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Neuroendocrine neoplasms are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

neuroendocrine neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Neuroendocrine neoplasms Neuroendocrine tumors

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    4 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Huadong Hospital Affiliated to Fudan University

    RECRUITING

    Shanghai, China

  • Huashan Hospital Affiliated to Fudan University

    RECRUITING

    Shanghai, China

  • Renji Hospital affiliated to Shanghai Jiaotong University School of Medicine

    RECRUITING

    Shanghai, China

  • Shanghai General Hospital shanghai jiao tong university school of medicine

    RECRUITING

    Shanghai, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.